Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SECOX vs Sorafenib in Advanced Hepatocellular Carcinoma
NCT02716766Phase 2Completed
- Sponsor
- The University of Hong Kong
- Start
- Mar 2016
- Primary completion
- Sep 2018
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, oxaliplatin in hepatocellular carcinoma (HCC), sponsored by The University of Hong Kong. Started Mar 2016; status: completed.
02
Drugs
capecitabineoxaliplatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02716766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02716766.